Compare Alexandria Real Estate Equities Inc (ARE) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Citius Pharmaceuticals Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.5 (market cap $8.28B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: Alexandria Real Estate Equities Inc is far larger — about 413.8× Citius Pharmaceuticals Inc's market cap, and Alexandria Real Estate Equities Inc pays a 5.99% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ARE | CTXR | |
|---|---|---|
Market Cap | $8.28B | $20.01M |
Sector | Real Estate | Health |
52-Week High | $87.45 | $1.82 |
52-Week Low | $40.41 | $0.48 |
Enterprise Value | $20.98B | $16.23M |
Dividend Yield | 5.99% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
